Stocks
SpringWorks Therapeutics, Inc.SWTX
NASDAQHealthcareBiotechnology$46.99+0.02%
Focused on developing targeted oncology therapies, this biopharmaceutical company specializes in rare cancers and precision medicine. Its lead drug candidate, nirogacestat, is in late-stage trials for desmoid tumors, drawing investor attention to its potential in underserved markets.
Market Cap: $3.5B52W Range: $28.21 – $62.00
Congressional Interest in SpringWorks Therapeutics, Inc. (SWTX)
3 members of Congress have disclosed 7 trades in SpringWorks Therapeutics, Inc. (SWTX), a Healthcare company. The buy/sell breakdown shows 4 purchases versus 3 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
7
Unique Politicians
3
Buys
4
Sells
3
Who in Congress Is Trading SWTX?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2025-07-02 | Josh Gottheimer | sell | $1K – $15K |
| 2025-07-01 | Gilbert Cisneros | sell | $15K – $50K |